LifeMD Posts Mixed Q1 2026: Revenue Up, EBITDA Loss Widens
Event summary
- Q1 2026 revenue of $50.2M, up from $50.9M in Q1 2025, beating guidance of $48M–$49M.
- Adjusted EBITDA loss of $4.5M, compared to a profit of $3.7M in Q1 2025.
- Gross margin expanded by 420 basis points to 88%, driven by favorable revenue mix and lower fulfillment costs.
- Record GLP-1 patient sign-ups with weight management revenues growing 120% sequentially.
- Women’s Health patient sign-ups surged 657% quarter-over-quarter with a 70% reduction in customer acquisition costs.
The big picture
LifeMD’s Q1 2026 results highlight its strategic shift from a telehealth-focused platform to a broader virtual healthcare provider. The company is leveraging its vertically integrated platform to support both direct-to-consumer and insurance-covered programs, positioning itself as a key player in the evolving digital health landscape. The significant growth in GLP-1 and Women’s Health segments underscores the demand for specialized virtual care services, but the widening EBITDA loss signals ongoing challenges in balancing growth with profitability.
What we're watching
- Revenue Growth
- Whether LifeMD can sustain its 120% sequential growth in weight management revenues and 657% surge in Women’s Health sign-ups.
- Profitability
- How the company will manage its adjusted EBITDA loss while scaling its insurance-sponsored offerings.
- Strategic Expansion
- The pace at which LifeMD can expand coverage to 230 million lives and integrate new product launches in men’s and women’s health.
Related topics